Vaccine doubles survival of deadly brain cancer
A cancer vaccine more than doubled the survival time of people with the most common and deadly type of brain tumor, U.S. researchers said on Monday.
Scientists pinpoint why some people become addictsThe vaccine, made by Avant Immunotherapeutics Inc and licensed by drug giant Pfizer Inc, enlists the help of the immune system to attack the tumor.
Researchers treated 23 patients with a type of brain tumor called glioblastoma multiforme. They have lived, on average, 33 months, said Dr. John Sampson of Duke University, who presented the study at a meeting of the American Society of Clinical Oncology in Chicago. "That is almost unheard of," Sampson said in an interview.
"We have one woman who has gone on to have two babies now," Sampson said.
Patients given standard therapy alone lived on average 14 months.
It also took far longer for tumors to grow back after surgery. In people treated with the vaccine, this so-called time to progression was 16.6 months, more than double the usual six months.
Avant shares surged on the news, rising nearly $4 or about 28 percent to $17.98 on Monday. Pfizer dipped slightly to close at $19.18.
Glioblastoma multiforme, a serious form of brain tumor of a type known as a glioma, kills half its victims within a year and patients rarely survive more than three years.
Massachusetts Democratic Sen. Edward Kennedy was diagnosed with a malignant glioma last month and the vaccine could be one among several options he might try, Sampson said.
"Kennedy may well be a candidate. We don't know if he is interested at this point," Sampson said in an interview.
- 1 Local private investors could miss an upturn
- 2 BoE expected to hold interest rates steady at 5 pct
- 3 Markets see ECB rates on hold through first half of yr
- 4 Fears of slowdown could veer China into trouble
- 5 BP Russian partners say row solved
- 6 U.S. corporates look to hedge as dollar rebounds
- 7 Utility windfall profits in tax spotlight
|
|
|
